CDKN2A and cancer: Although the impact of p16 hypermethylation on prognosis of patients with cancer has been explored recently, the prognostic value of p16 hypermethylation in different tumor types remains conflicting because heterogeneous results were reported in studies and some of them included a small number of patients.